Both malignancies share common ancestral mutations in TET2 and/or DNMT3A, while disease specific mutations result in the emergence of the AITL (RHOA, TCR signaling) or myeloid disease (NPM1)93 (Fig. 3). This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.